

# Social Value Creation

We recognize that the social value created through our Materiality initiatives will be from the Group's contribution to United Nations (UN) Sustainable Development Goals (SDGs).

We have organized an outline of the social significance of the Group's initiatives in terms of Purpose, Vision, and Materiality, and summarized our progress in achieving our Purpose (creation of social value) in the below chart. Furthermore, we organized the social value that our Group is creating from the perspective of the UN SDGs. For example, "to contribute to the enrichment of quality of life around the world" to which society has high expectations and to which we can best contribute, is linked to UN SDGs Goal 3, "Ensure healthy lives and promote well-being for all at all ages." We will also contribute to the achievement of Goals 9, 12, and 17 of the UN SDGs to realize our Purpose. In addition, to promote environmental management, we are endeavoring to meet the growing societal demand for "contribution to environmental load reduction". Furthermore, through our Materiality of "promoting compliance management" and "corporate governance aimed at fulfilling our mission", we strive to realize highly transparent management along with promotion and development of talent so that each and every employee can find their work rewarding, solidifying our commitment to respect for human rights and thereby contributing to our achievement of Goals 5, 8, 10, and 16 of the UN SDGs.

In light of the external environment surrounding our Group, we are working to promote a deeper understanding of the SDGs within the Group companies, therefore each and every employee will be encouraged to take ownership in contributing to the SDGs as part of a company-wide effort to create social value. We will continue to work together as a Group to solve social issues not only by growing as a business, but also through creating new value.



**Purpose**

**Contribute to the enrichment of quality of life around the world**

**2030 Vision**

**Innovative global healthcare company contributing to the sustainable development of society**

## Materiality on Business

**Continuously create innovative pharmaceuticals and provide pharmaceuticals addressing diverse medical needs**

## Materiality on Business Foundations

**To achieve our goal of carbon neutrality by 2050 and, as a healthcare company, proactively reduce the environmental impact of our business operations and implement advanced climate change countermeasures**

### Daiichi Sankyo Co., Ltd.

Delivered *Enhertu*<sup>®</sup>, an oncology drug that addresses the unmet medical need for cancer treatment and innovates the standard of care, to more patients around the world by adding new indications and expanding approvals in more countries.

Produced and shipped AstraZeneca's COVID-19 vaccine as a contract manufacturing business by using Daiichi Sankyo Biotech's existing production facilities to restore the sense of safety and security in society, and contributed to providing the vaccine to Southeast Asia and other countries through the Japanese government.

Launched *Delytact*<sup>®</sup> in Japan for the treatment of malignant glioma, providing a new treatment option for patients with rare diseases that have few alternatives available because of the difficulty in developing treatments.

Capacity building through launching a cancer screening camp and providing services to over 1,000 local residents in Nepal, where breast and cervical cancer incidence rate is high and accounts for 30% of all cancer-related mortality.


### Daiichi Sankyo, Inc.

Ensured patient access to investigational products (products not yet granted regulatory approval) through the Expanded Access Programs, which provide patients who are suffering from life-threatening conditions where there is an unmet medical need that cannot be met by existing products and who are unable to participate in clinical trials.

### Daiichi Sankyo Espha Co., Ltd.

Provided high value-added generic drugs which are easier for patients to take and prevent medication-related errors, by printing the names on the tablet and focusing on designing the symbol mark on the PTP\*.

\* Abbreviation of Press Through Package



### Daiichi Sankyo Co., Ltd.

Secured a stable supply of the comparator drugs necessary for clinical trials and established waste reduction by reviewing bulk purchases and devising other procurement methods.

Reduced person-hours, organic solvents and reagents, and energy consumption during production by improving the manufacturing process for narcotic active pharmaceutical ingredients (APIs).

### Daiichi Sankyo Europe GmbH

Started operation of a self-consumption solar power system at the Pfaffenhofen Plant and reduced annual CO<sub>2</sub> emissions by approximately 230 tons. In addition, as part of the initiatives to realize a decarbonized society, we are actively promoting the installation of charging stations to support the adoption of electric vehicles.

### Daiichi Sankyo Espha Co., Ltd.

Promoted the use of biomass plastic bottles in bulk packaging, which realized reduction of CO<sub>2</sub> emissions and the amount of petrochemical resin used compared to petroleum-derived plastics.

### Daiichi Sankyo Healthcare Co., Ltd.

Switched to FSC<sup>®</sup>-certified paper for individual packaging boxes for approximately 40 products, making our packaging and materials environmentally friendly.

Please refer to our website for more details on our initiatives.

[Click here for more information.](https://www.daiichisankyo.com/sustainability/our_approach/sdgs/) [https://www.daiichisankyo.com/sustainability/our\\_approach/sdgs/](https://www.daiichisankyo.com/sustainability/our_approach/sdgs/)